Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial

Journal of Thoracic Oncology

Volumn 8, Issue 7, 2013, Pages 930-939

  Nicolson, Marianne C ^a   Fennell, Dean A ^b   Ferry, David ^c   O'Byrne, Kenneth ^d,e   Shah, Riyaz ^f   Potter, Vanessa ^g   Skailes, Geraldine ^h   Upadhyay, Sunil ⁱ   Taylor, Paul ^j   André, Valerie ^j   Nguyen, Tuan S ^j   Myrand, Scott P ^j   Visseren Grul, Carla ^j   Das, Mayukh ^j   Kerr, Keith M ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^c NEW CROSS HOSPITAL   (United Kingdom)

^d ST JAMES S HOSPITAL   (Ireland)

^e MAIDSTONE HOSPITAL   (United Kingdom)

^f NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^g ROYAL PRESTON HOSPITAL   (United Kingdom)

^h Northern Lincolnshire and Goole Hospitals NHS Foundation Trust   (United Kingdom)

ⁱ MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^j ELI LILLY AND COMPANY   (United States)

more..

Author keywords

Non small cell lung cancer; Pemetrexed; Thymidylate synthase expression; Translational research

Indexed keywords

CISPLATIN; CYANOCOBALAMIN; DEXAMETHASONE; FOLIC ACID; MESSENGER RNA; PEMETREXED; THYMIDYLATE SYNTHASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CONFIDENCE INTERVAL; CYTOPLASM; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION;

EID: 84880916275     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318292c500     Document Type: Article

References (28)

1. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy- naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
2. D'Addario G, Früh M, Reck M, Baumann P, Klepetko W, Felip E; ESMO Guidelines Working Group. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. Ann Oncol 2010;21 Suppl 5:v116-v119.
3. Azzoli CG, Baker S Jr, Temin S, et al.; American Society of Clinical Oncology. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009;27:6251-6266.
4. National Institute for Health and Clinical Excellence (NICE). Technology appraisal guidance 181. Pemetrexed for the first-line treatment of nonsmall- cell lung cancer. September 2009. Available at: http ://www .nice .org.uk/nicemedia/live/12243/45501/45501.pdf. Accessed November 15, 2012.
5. Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a doubleblind, phase 3, randomised controlled trial. Lancet Oncol 2012;13: 247-255.
6. Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo[2,3-d]pyrimidine- based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997;57:1116-1123.
7. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006;107:1589-1596.
8. Sun JM, Han J, Ahn JS, Park K, Ahn MJ. Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. J Thorac Oncol 2011;6:1392-1399.
9. Chen CY, Chang YL, Shih JY, et al. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed. Lung Cancer 2011;74:132-138.
10. Sigmond J, Backus HH, Wouters D, Temmink OH, Jansen G, Peters GJ. Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 2003;66:431-438.
11. Takezawa K, Okamoto I, Okamoto W, et al. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer. Br J Cancer 2011;104:1594-1601.
12. Santi DV. The mechanism and structure of thymidylate synthetase. Nucleic Acids Symp Ser 1986;17:125-126.
13. Bissoon-Haqqani S, Moyana T, Jonker D, Maroun JA, Birnboim HC. Nuclear expression of thymidylate synthase in colorectal cancer cell lines and clinical samples. J Histochem Cytochem 2006;54:19-29.
14. Kerr KM, Fennell DA, Shah RN, et al. Thymidylate synthetase (TS) immunohistochemistry (IHC): feasibility in a routine clinical setting for patients receiving treatment with pemetrexed for advanced nonsquamous NSCLC. J Clin Oncol 2010;28 (suppl; abstr TPS293).
15. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
16. Fennell DA, Nicolson M, Ferry D, et al. Suitability of advanced non-small cell lung cancer biopsies for prospective, multiple molecular analysis in clinical trials. Eur J Cancer 2011;47:S17 PP56 (suppl; abstr 4).
17. Tanney A, Kennedy RD. Developing mRNA-based biomarkers from formalin- fixed paraffin-embedded tissue. Per Med 2010;7:205-211.
18. Rubinstein RY, Kroese DP. Simulation and the Monte Carlo Method (2nd Ed.), New York, NY: John Wiley & Sons 2007.
19. Miller R, Siegmund D. Maximally selected Chi-square statistics. Biometrics 1982;38:1011-1016.
20. Kaplan EL, Meier P. Nonparametric estimation of incomplete observations. J Am Statist Assoc 1958;53:457-481.
21. Collett D. Modelling Survival Data in Medical Research. London, United Kindom: Chapman and Hall/CRC; 1994.
22. Leemis LM, Trivedi KS. A comparison of approximate interval estimators for the Bernoulli Parameter. Amer Stat 1996;50:63-68.
23. Gianoncelli L, Toschi L, Canal B, et al. Expression of folate pathway regulators and pemetrexed (pem) activity in patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2012;30 (suppl; abstr 7585).
24. Hou J, Lambers M, den Hamer B, et al. Expression profiling-based subtyping identifies novel non-small cell lung cancer subgroups and implicates putative resistance to pemetrexed therapy. J Thorac Oncol 2012;7:105-114.
25. Ozasa H, Oguri T, Uemura T, et al. Significance of thymidylate synthase for resistance to pemetrexed in lung cancer. Cancer Sci 2010;101:161-166.
26. Hosomi Y, Satouchi M, Mori K, et al. Prospective multicenter study of pemetrexed and carboplatin combination followed by maintenance pemetrexed in chemo-naïve patients with non-squamous non-small cell Lung Cancer. Eur J Cancer 2011;47:S631-S632 (suppl; abstr 9128).
27. Paz-Ares L, De Marinis F, Dediu M, et al. PARAMOUNT: final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). J Clin Oncol 2012;30 (suppl; abstr LBA 7507).
28. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for nonsmall- cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-1440.